

Trabikibart

Cat. No.:	HY-P990094
CAS No.:	2643974-98-3
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Trabikibart (CSL311), a β c-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human β c receptor. Trabikibart has picomolar binding affinity for the human β c receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research^[1].

REFERENCES

[1]. Con Panousis, et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors. *MAbs*. 2016;8(3):436-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA